The Promise of Cell Therapy Approaches in Epilepsy
Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Jonathan Parker, MD, PhD.
Epilepsy Cell Therapy NRTX-1001 May Eventually Be Evaluated for Alzheimer Disease
Cory R. Nicholas, PhD, the cofounder and CEO of Neurona Therapeutics, discussed future plans for the expanded applications of the allogeneic regenerative neural cell therapy.
Neurona Therapeutics NRTX-1001 Has Shown Promising Early Signs of Safety and Efficacy in Drug-Resistant Epilepsy
Cory R. Nicholas, PhD, the cofounder and CEO of Neurona Therapeutics, discussed the ongoing first-in-human clinical trial evaluating the cell therapy for drug-resistant mesial temporal lobe epilepsy.
Cell Therapy May Help to Address Unmet Needs in Epilepsy
Cory R. Nicholas, PhD, the cofounder and CEO of Neurona Therapeutics, discussed NRTX-1001, the company’s allogeneic regenerative neural cell therapy currently being evaluated in MTLE.
Cory R. Nicholas, PhD, on Future Plans for Additional Research With Epilepsy Cell Therapy NRTX-1001
The cofounder and CEO of Neurona Therapeutics discussed the company’s goals to evaluate the cell therapy in more types of epilepsy and potentially even in Alzheimer disease.
Cory R. Nicholas, PhD, on Initial Efficacy and Safety Results With NRTX-1001 in Mesial Temporal Lobe Epilepsy
The cofounder and CEO of Neurona Therapeutics discussed results from a phase 1/2 clinical trial presented at AES’s annual meeting.
Neurona's Interneuron Cell Therapy Looks Promising in Drug-Resistant Mesial Temporal Lobe Epilepsy
The trial is recruiting 5 more participants for the highest dose cohort following a positive DSMB review.
Cory R. Nicholas, PhD, on Addressing Unmet Needs in Mesial Temporal Lobe Epilepsy With Cell Therapy
The cofounder and CEO of Neurona Therapeutics discussed NRTX-1001, the company’s allogeneic regenerative neural cell therapy.
AMT-260 miRNA Gene Therapy Displays Preclinical Promise Ahead of First-in-Human Trial
uniQure’s AAV9-vector therapy carrying 2 small interfering RNAs targeting GRIK2 was well-tolerated, with a hopeful risk-benefit ratio. A phase 1/2 is set to begin recruitment in late 2023.
